At a glance
ClinicalIndex Comparison RecordN/ACompleted· 101 enrolled
Drug / intervention
Bioabsorbable Everolimus Eluting Coronary Stentdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System (BVS EECSS) in the Treatment of Patients With de Novo Native Coronary Artery Lesions.
In Brief
A clinical study evaluating Bioabsorbable Everolimus Eluting Coronary Stent for Coronary Disease and 2 related conditions. Completed, enrolled 101 participants across 12 sites in 8 countries.
Detailed Summary
The purpose of this study is to assess the safety and performance of the BVS Everolimus Eluting Coronary Stent System (EECSS) in the treatment of patients with a maximum of two de novo native coronary artery lesions located in two different major epicardial vessels. Currently in development at Abbott Vascular. Not available for sale in the United States.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Belgium, Denmark, France, Netherlands, New Zealand, Poland, Switzerland
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2009
First PostedMar 2009
Primary CompletionOct 2015
Study CompletionMar 2016
TodayJul 2026
First PostedMar 6, 2009
Enrollment StartMar 1, 2009
Primary CompletionOct 1, 2015
Study CompletionMar 1, 2016
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 17.3 years ago
Interventions
Bioabsorbable Everolimus Eluting Coronary Stentdevice
Bioabsorbable drug eluting stent implantation in the treatment of coronary artery disease